| The impact of perceived organizational support and resilience on pharmacists’ engagement in their stressful and competitive workplaces in Saudi Arabia HA Al-Omar, AM Arafah, JM Barakat, RD Almutairi, F Khurshid, ... Saudi Pharmaceutical Journal 27 (7), 1044-1052, 2019 | 105 | 2019 |
| The ticking time bomb in lifestyle-related diseases among women in the Gulf Cooperation Council countries; review of systematic reviews MK Alshaikh, FT Filippidis, HA Al-Omar, S Rawaf, A Majeed, AM Salmasi BMC public health 17, 1-17, 2017 | 53 | 2017 |
| Prescribing of potentially inappropriate medications among the elderly population in an ambulatory care setting in a Saudi military hospital: trend and cost HA Al‐Omar, MS Al‐Sultan, HS Abu‐Auda Geriatrics & gerontology international 13 (3), 616-621, 2013 | 44 | 2013 |
| Pharmacists' understanding and attitudes towards pharmaceutical care in Saudi Arabia MN Al-Arifi, AA Al-Dhuwaili, OA Gubara, HA Al-Omar, MS Al-Sultan, ... Saudi Pharmaceutical Journal 15 (2), 146-159, 2007 | 38 | 2007 |
| Assessing the level of knowledge and available sources of information about hepatitis C infection among HCV-infected Egyptians NY Sultan, A YacoobMayet, SA Alaqeel, HA Al-Omar BMC Public Health 18, 1-8, 2018 | 28 | 2018 |
| Criteria to define rare diseases and orphan drugs: a systematic review protocol GM Abozaid, K Kerr, A McKnight, HA Al-Omar BMJ open 12 (7), e062126, 2022 | 15 | 2022 |
| Impact of a multidisciplinary intensive education program on type 2 diabetes mellitus patients’ glycemic control and cardiovascular risk factors MN Al-Arifi, HA Al-Omar Saudi Medical Journal 39 (7), 705, 2018 | 15 | 2018 |
| Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia NA Alsaleh, HA Al-Omar, AY Mayet, AB Mullen Saudi Pharmaceutical Journal 28 (11), 1492-1498, 2020 | 13 | 2020 |
| Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia HA Al-Omar, AA Attuwaijri, IA Aljuffali Saudi Pharmaceutical Journal 28 (6), 662-668, 2020 | 13 | 2020 |
| What local experts expect from a health technology assessment (HTA) entity in Saudi Arabia: workshop conclusions HA Al-Omar, AA Attuwaijri, IA Aljuffali Expert review of pharmacoeconomics & outcomes research 20 (1), 99-104, 2020 | 13 | 2020 |
| Pharmacy students' use, knowledge and attitudes toward complementary and alternative medicine at Riyadh region, Saudi Arabia HA Al-Omar, MN Al-Arifi International Journal of Green Pharmacy (IJGP) 5 (1), 2011 | 13 | 2011 |
| Vaccination status of patients using anti-TNF therapy and the physicians’ behavior shaping the phenomenon: Mixed-methods approach HA Al-Oma, HM Sherif, AY Mayet PLoS ONE, 2019 | 10 | 2019 |
| Cost-conscious medications-prescribing behavior among physicians working in Saudi Arabia HA Al-Omar Archives of Pharmacy Practice 11 (1), 143-152, 2020 | 9 | 2020 |
| Rivaroxaban prescribing in a Saudi tertiary care teaching hospital AY Mayet, AI Alsaqer, AM Alhammad, HA Al-Omar Saudi Pharmaceutical Journal 26 (6), 775-779, 2018 | 9 | 2018 |
| Obesity burden and impact of weight loss in Saudi Arabia: A modelling study SA Alqahtani, HA Al-Omar, A Alshehri, A Abanumay, H Alabdulkarim, ... Advances in Therapy 40 (3), 1114-1128, 2023 | 8 | 2023 |
| Budget impact analysis of transcatheter aortic valve replacement in low, intermediate, and high-risk patients with severe aortic stenosis in Saudi Arabia JL Carapinha, HA Al-Omar, F Alqoofi, SA Samargandy, P Candolfi Journal of Medical Economics 25 (1), 77-86, 2022 | 7 | 2022 |
| Value drivers for pharmaceutical products in health technology assessment (HTA) in Saudi Arabia: Results from a capacity Building, Multi-Stakeholder workshop HA Al-Omar, IA Aljuffali, O Solà-Morales Saudi Pharmaceutical Journal 29 (9), 946-954, 2021 | 7 | 2021 |
| Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach HA Al-Omar, HH Alghannam, IA Aljuffali Expert Review of Pharmacoeconomics & Outcomes Research, 2020 | 6 | 2020 |
| Prevalence of the co-prescription of tamoxifen and CYP2D6 inhibitors in Saudi population: A cross sectional study A Arafah, K Yakout, MU Rehman, AM Alsharif, MH AlJawadi, HA Al-Omar Saudi Pharmaceutical Journal 28 (4), 440-444, 2020 | 6 | 2020 |
| The impact of obesity in Saudi Arabia: healthcare resource use and costs associated with obesity-related complications HA Al-Omar, A Alshehri, A Abanumay, H Alabdulkarim, A Alrumaih, ... Advances in Therapy 40 (4), 1430-1443, 2023 | 4 | 2023 |
